To access this element change to forms mode OFF
Grant Award View - GA89317
Precision Medicine for Chronic Myelomonocytic Leukaemia: Phase II Trial...
GA ID:
GA89317
Agency:
Department of Health and Aged Care
Approval Date:
25-May-2020
Publish Date:
29-Jun-2020
Category:
Health and Medical Research
Grant Term:
1-Jun-2020 to 31-May-2023
Value (AUD):
$1,619,122.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 19/20 1.1 Health Policy Research and Analysis
Grant Program:
2019_MRFF_RCRDUN_RCRDUN_2020
Grant Activity:
Precision Medicine for Chronic Myelomonocytic Leukaemia: Phase II Trial Studying the Efficacy of Lenzilumab or High Dose Ascorbate plus Azacitidine Based on Molecular Profiling Compared to Risk-matched Historical Cohort
Purpose:
Chronic myelomonocytic leukaemia is a rare and neglected blood cancer that rapidly progresses to acute leukaemia within 28-32 months and has no approved therapy. Based on our extensive data we will treat high risk newly diagnosed patients with a new monoclonal antibody Lenzilumab and metabolic interventions (including high dose ascorbate) plus standard of care azacitidine and assess the percentage of patients that have not progressed and still alive.
GO ID:
GO Title:
MRFF Clinical Trials Activity - RCRDUN Initiative – 2019 Rare Cancers, Rare Diseases and Unmet Need Grant Opportunity
Internal Reference ID:
MRF1201012
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Adelaide
Recipient ABN:
61 249 878 937
Grant Recipient Location
Suburb:
Adelaide
Town/City:
Adelaide
Postcode:
5000
State/Territory:
SA
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
SA
Postcode:
Country:
AUSTRALIA